GLP-1 Injection Sites Compared: Abdomen vs. Thigh vs. Upper Arm
For the weekly GLP-1 injections, the site you choose does not change how much medicine your body absorbs. The Wegovy and Zepbound labels both say exposure is similar whether you inject into the abdomen, thigh, or upper arm. So the real choice comes down to comfort, who is doing the injecting, and rotating well enough to keep the skin healthy.
Key takeaways
- FDA labels for semaglutide (Wegovy) and tirzepatide (Zepbound) report similar drug exposure across the abdomen, thigh, and upper arm.
- No study has compared weight loss or side effects by injection site. Lilly says this "has not been studied."
- Zepbound's label says to rotate injection sites with each dose, and that another person should give upper-arm injections.
- Injection-technique guidance says GLP-1 injections don't appear to cause the fatty lumps (lipohypertrophy) seen with insulin, but it still recommends rotating.
- Your body weight affects tirzepatide levels much more than which site you use.
What the labels actually say about each site
All three approved sites appear in the prescribing information, and none is called preferred. The Wegovy label, in the version FDA approved in May 2026, says to "inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm." It also says that "the time of day and the injection site can be changed without the need for a dosage modification" (FDA Wegovy approval package, May 2026).
Zepbound's label is a bit more specific. Its August 2026 revision tells patients to inject in the abdomen or thigh, and says another person should give the injection in the back of the upper arm. It also says to "rotate injection sites with each dose" (Zepbound prescribing information, rev. 08/2026). The pen's Instructions for Use repeat this. They say you may use the same body area each week, but you should pick a different spot within it (Zepbound Pen Instructions for Use, April 2026).
Daily liraglutide (Saxenda) lists the same three sites. Its label says no dose change is needed if you switch sites or change the time you inject (Saxenda prescribing information, rev. 02/2026).
| Factor | Abdomen | Thigh | Upper arm (back) |
|---|---|---|---|
| Listed on Wegovy and Zepbound labels | Yes | Yes | Yes |
| Drug exposure vs. other sites (per labels) | Similar | Similar | Similar |
| Comparative efficacy or side-effect data | None published | None published | None published |
| Self-injection per Zepbound IFU | Yes | Yes | Another person should inject |
| Room for rotating within the area | Large area | Large area (front and outer thigh) | Smaller area |
| Practical notes | Easy to see and reach. Keep away from the navel and any scars. | Easy to reach while seated. Good option if belly skin is sensitive. | Hard to pinch and reach yourself. Best with a helper. |
Source: Wegovy and Zepbound FDA labeling (2026), Zepbound Pen Instructions for Use (April 2026), Lilly Medical Information. "Practical notes" sum up general injection-technique guidance, not trial outcomes.
The pharmacokinetic evidence: similar exposure, no outcome trials
The labels base their "similar exposure" statements on pharmacokinetic studies, which measure blood levels of the drug. They did not measure weight loss. For semaglutide, section 12.3 of the Wegovy label says: "Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm." The same section puts absolute bioavailability after an injection at 89%, with peak levels 1 to 3 days after a dose (FDA Wegovy approval package).
The Zepbound label uses nearly identical wording for tirzepatide (Zepbound prescribing information). Lilly's population pharmacokinetic analysis lists the underlying study: one 5 mg dose given in the upper arm, thigh, or abdomen to healthy participants (Schneck & Urva, CPT: Pharmacometrics & Systems Pharmacology, 2024).
Lilly is careful not to overstate this. Its medical information page says "there is no data from studies comparing these injection sites to assess efficacy and safety differences." It adds that Lilly cannot comment on differences between approved sites "because this has not been studied" (Lilly Medical Information).
That means claims that "belly injections work better" or "thigh shots cause less nausea" are not supported by published trials. Drug levels look the same across sites, and no one has measured whether outcomes differ.
What matters more than site: body weight
The same Lilly analysis found that body weight shifts tirzepatide exposure much more than injection site does. Exposure changed by about 1.1% per kilogram across 70 to 120 kg. Compared with a typical 90 kg person, exposure was about 22% higher at 70 kg and about 33% lower at 120 kg (Schneck & Urva, 2024). This is one reason prescribers adjust the dose based on your response, not your injection site.
Comparing GLP-1 options?
See current programs and what they charge before you choose a provider.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Rotation and lipohypertrophy: what applies to GLP-1s
Lipohypertrophy means thickened, rubbery lumps of fat under skin that has been injected too often. It is well documented with insulin. Forum for Injection Technique (FIT) Canada cites international studies reporting a prevalence of 49% to 64% or higher among insulin users. Insulin injected into these lumps is absorbed less predictably, and not rotating sites is the factor most strongly linked to them (FIT Canada Recommendations, 4th ed., 2020).
GLP-1s look different. The same FIT Canada document says "the available evidence indicate that GLP-1 receptor agonist injections do not lead to lipohypertrophy." It still calls rotation "important" with these drugs. It also advises against injecting GLP-1s into lumpy areas, while noting that no study has tested this directly. In the same document, FIT Canada says GLP-1 receptor agonists "are absorbed equally from each of the usual injection sites (i.e. abdomen, arm and thigh)" (FIT Canada, 2020).
A weekly shot also means far fewer injections than multiple daily insulin doses, so the repeated-trauma problem is much smaller. Still, rotating costs nothing and lines up with the Zepbound label.
How rotation is usually described
Injection-technique guides describe a simple system:
- Divide each area into zones, such as four quadrants of the abdomen.
- Use one zone at a time and move through them in a set order.
- Keep each new injection at least 1 to 2 cm (about a finger's width) from the last one (FIT Canada, 2020).
A UK primary-care guide adds that rotating in a consistent pattern protects against lipohypertrophy far better than picking sites at random (Diabetes & Primary Care, "How to" injection technique). Insulin guidance summarized from Mayo Clinic Proceedings in 2025 also says to avoid scars, stretch marks, tattoos, and skin that is swollen, infected, or inflamed (Guideline Central summary, May 2025). That advice was written for insulin, but it is sensible for any injection under the skin.
Injection site reactions: how common, and does site matter?
Redness, itching, or a small bump where you injected are the most common skin complaints. They are usually mild. With Wegovy, 1.4% of patients in the adult weight-loss trials reported injection site reactions, compared with 1% on placebo (Wegovy label).
Tirzepatide's rates are higher. Lilly reports 2.1% to 11.1% in tirzepatide-only groups across SURMOUNT-1 through -4. In the head-to-head SURMOUNT-5 trial, the rate was 8.6% with tirzepatide versus 0.3% with semaglutide. Lilly states that "none of the injection site reactions were reported as severe or serious." Reactions were more common in people who developed anti-tirzepatide antibodies: 11.3% versus 1% in a pooled analysis (Lilly Medical Information, reviewed Dec. 2025).
That same page does not break reactions down by body site. If one area keeps reacting, switching sites is reasonable, but no published data shows one site reacts less than another.
Choosing a site: practical tradeoffs
Abdomen
The abdomen offers the biggest area for rotating and is easy to see. That helps if you're new to injecting or using a vial and syringe. Its drawback is that skin irritation can be more noticeable in a spot you see every day. Waistbands can also rub a fresh site.
Thigh
The front and outer thigh are easy to reach while sitting, and the area is large enough for a full rotation. Some people switch to the thigh when belly skin becomes sensitive. The labels show no difference in exposure, so this is purely a comfort choice.
Upper arm
The back of the upper arm is hard to reach yourself. That's why the Zepbound label and IFU say another person should inject there (Zepbound IFU). It works well if a partner or caregiver helps. It's also a good way to add a third area to your rotation.
Does site matter for vials, pens, or higher doses?
The label exposure statements apply to the drug, not the device. Wegovy now includes a 7.2 mg dose (Wegovy HD) and a manual prefilled syringe, and its site instructions are the same three areas (FDA Wegovy approval package). With a vial, the bigger risk is measuring the dose wrong, not picking the wrong site. Have your pharmacist or prescriber walk you through drawing up the dose.
The verdict
Pick the site you can inject consistently and comfortably, then rotate. On absorption, the abdomen, thigh, and upper arm are equivalent according to the FDA labels for Wegovy and Zepbound. No trial shows any site gives better weight loss or fewer side effects. The abdomen is easiest for new self-injectors. The thigh is a good alternative when belly skin is irritated. The upper arm works best when someone else does the injection. Whatever area you use, move each injection at least a finger's width from the last one, skip scars and irritated skin, and tell your prescriber about reactions that get worse instead of better.
Still deciding on a GLP-1?
Look at current pricing and formats from licensed providers side by side.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Is it better to inject Wegovy or Zepbound in the stomach or the thigh?
Neither is better for absorption. The FDA labels for both drugs say exposure is similar in the abdomen, thigh, and upper arm, and no study has compared weight loss or side effects by site.
Do I need to rotate GLP-1 injection sites?
Yes. The Zepbound label says to rotate injection sites with each dose. Injection-technique guidance also recommends rotation for GLP-1s, even though the evidence suggests they don't cause the lipohypertrophy seen with insulin.
Can I inject Zepbound in my own arm?
The Zepbound label and Instructions for Use say another person should give injections in the back of the upper arm. You can inject the abdomen and thigh yourself.
Are injection site reactions more common in one area?
Published data don't break reactions down by site. Lilly reports reaction rates of 2.1% to 11.1% across SURMOUNT-1 to -4, none severe. Wegovy's label reports 1.4% versus 1% on placebo.
Does body weight affect GLP-1 levels more than injection site?
For tirzepatide, yes. Lilly's population analysis found exposure about 33% lower at 120 kg than at 90 kg, a much bigger difference than any reported between sites.
Sources
- FDA: Wegovy (semaglutide) approval package and labeling, NDA 215256/S-031, May 2026
- Eli Lilly: Zepbound prescribing information (rev. 08/2026)
- Eli Lilly: Zepbound Pen Instructions for Use (rev. April 2026)
- Novo Nordisk: Saxenda prescribing information (rev. 02/2026)
- Lilly Medical Information: Safety or efficacy differences by Zepbound injection site
- Schneck K, Urva S. Population pharmacokinetics of tirzepatide. CPT Pharmacometrics Syst Pharmacol, 2024
- Lilly Medical Information: Injection site reactions in the SURMOUNT studies
- FIT Canada: Optimizing Injection Technique in Diabetes, 4th edition (2020)
- Diabetes & Primary Care: How to support best practice injection technique
- Guideline Central: Insulin injection technique guidelines spotlight (May 2025)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.